Try our beta test site
408 studies found for:    "Expanded Access" [STUDY-TYPES]
Show Display Options
RSS Create an RSS feed from your search for:
"Expanded Access" [STUDY-TYPES]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Available Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Condition: Metastatic Merkel Cell Carcinoma
Intervention: Drug: Avelumab
2 No longer available Treatment With Crizotinib Single Patient Expanded Access IND 134375
Condition: Inflammatory Myofibroblastic Tumour
Intervention: Drug: Crizotinib
3 Available Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Condition: Ovarian Cancer
Intervention: Drug: Olaparib tablets
4 Available Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease
Conditions: Cholestasis;   Liver Diseases
Intervention: Drug: Omegaven
5 Available Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Conditions: Acute Myeloid Leukemia (AML);   FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Intervention: Drug: ASP2215
6 Available Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
Condition: Recurrent GBM
Intervention: Biological: rindopepimut
7 Available Individual Patient Expanded Access-Glembatumumab Vedotin
Condition: Metastatic gpNMB Expressing Triple Negative Breast Cancer
Intervention: Drug: glembatumumab vedotin
8 Available Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
Condition: Cancers With NTRK, ROS1, or ALK Gene Fusions
Intervention: Drug: Entrectinib
9 Temporarily not available Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients
Condition: PSR Ovarian Cancer With a BRCA Mutation
Intervention: Drug: olaparib
10 Available Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome
Conditions: Congenital Myasthenic Syndrome;   Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4-Diaminopyridine
11 Available Expanded Access to RXDX-105 for Cancers With RET Alterations
Condition: Cancers With RET Alterations
Intervention: Drug: RXDX-105
12 Available Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma
Condition: Ewing Sarcoma
Intervention: Drug: Ganitumab
13 Available Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Intervention: Drug: Niraparib
14 Available Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion
Conditions: Cancer;   Neurotrophic Tyrosine Kinase, Receptor-related Proteins
Intervention: Drug: larotrectinib
15 Available Dupilumab Compassionate Use Study
Condition: Asthma
Intervention: Drug: Dupilumab
16 Temporarily not available A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
Conditions: Neuroblastoma;   Pheochromocytoma
Intervention: Drug: 131-I-meta-iodobenzylguanidine
17 Available Study of Cannabidiol for Drug-Resistant Epilepsies
Condition: Drug Resistant Epilepsy
Intervention: Drug: Cannabidiol
18 Temporarily not available Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
Conditions: CMV Viremia;   CMV Disease
Intervention: Biological: Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
19 No longer available Single Patient IND, MLN8237
Condition: Prostate Cancer
Intervention: Drug: MLN8237
20 Available An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC
Conditions: Malignant Neoplasms of Digestive Organs;   Neuroendocrine Tumor;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
Interventions: Drug: 68Ga-DOTATOC;   Procedure: PET/CT

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.